Sanofi
SNYNF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 5.92 | -0.59 | 0.39 | -0.36 |
| FCF Yield | 5.13% | 7.63% | 7.40% | 7.78% |
| EV / EBITDA | 11.35 | 11.09 | 8.96 | 10.79 |
| Quality | ||||
| ROIC | 10.99% | 10.35% | 10.12% | 6.36% |
| Gross Margin | 70.18% | 69.35% | 78.64% | 68.72% |
| Cash Conversion Ratio | 1.65 | 1.90 | 1.26 | 1.69 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.19% | 5.84% | 2.55% | 1.35% |
| Free Cash Flow Growth | -31.87% | 3.77% | -1.82% | 58.93% |
| Safety | ||||
| Net Debt / EBITDA | 0.95 | 0.88 | 0.63 | 1.09 |
| Interest Coverage | 19.29 | 18.28 | 28.28 | 22.08 |
| Efficiency | ||||
| Inventory Turnover | 1.40 | 1.47 | 1.53 | 1.41 |
| Cash Conversion Cycle | 139.57 | 146.71 | 154.54 | 166.69 |